Sun Pharmaceutical Industries Limited

Sun Pharmacuetical Industries Ltd.

Sun Pharmaceutical Indsutries Ltd.

Samarth Kumar

Prashant Kane

Subhas Balaram Bhowmick

Maheshkumar Parasmal Soni

Kirti Ganorkar

Nishit Patel

Nisarg Bipinchandra Mistry

Ramaji Karshanbhai Varu

Praveen Kumar Srivastava

Milan Mohanbhai Vasoya

Shantaram Pawar

Kandarp Maheshkumar Dave

Milan Natvarbhai Thakkar

Mark Hagler

Sapna Fadnis

Kartik Nagar

Raman Lad

Amar Rana

Swapnil Ramesh Patil

Rajamannar Thennati

Rakesh Thummar

Alok B Namdeo

Umeshkumar Mukeshbhai Patel

Ashish Anilrao Dubewar

Mukeshbhai Umeshkumar Patel

Anilrao Ashish Dubewar

Balaram Subhas Bhowmick

Soni Maheshkumar Parasmal

Ramaji Karshanbhai Mistry

Hishit Patel

Subhas Balaram Browmick

Subhas B Bhowmick

A parenteral dosage form having an infusion container filled with an aqueous solution in volumes ranging from 40 ml to 500 ml comprising 1 mg/ml to 2 mg/ml of carboplatin, wherein the solution contains known impurity of 1, 1-cyclobutanedicarboxylic acid in an amount of not more than 1.0% by weight of carboplatin and the solution remains physically stable when stored at room temperature.

Parenteral dosage form of carboplatin

The present invention refers to an intravenous infusion dosage form comprising a composition containing pemetrexed or its pharmaceutically acceptable salt, an osmagent and an aquous vehicle. The composition is present in a flexible infusion container containing an inert gas in the headspace. Additionally, a second container may be present surrounding the flexible infusion container.

Intravenous infusion dosage form

The present invention relates to a dosage form comprising an aqueous solution of a vinca alkaloid drug or its pharmaceutically acceptable salt in a flexible infusion container, and a light protective secondary packaging containing the flexible infusion container, wherein the dosage form is ready-to-infuse and wherein the aqueous solution is stable at room temperature.

Dosage form of vinca alkaloid drug

The present invention provides a ready to use stable aqueous dosage form of norepinephrine comprising an aqueous solution of norepinephrine or its pharmaceutically acceptable salt, one or more sulfite antioxidants and an ion chelator. The present invention also provides an infusion container filled with an aqueous solution of norepinephrine or its pharmaceutically acceptable salt, wherein the said solution is stable for a prolonged period of time and can be terminally sterilized by autoclaving.

Infusion dosage form of norepinephrine

A perfusion container for directly administering to patients a dose of an antineoplastic drug calculated according to a patient's parameter, wherein the first perfusion container comprises a solution of antineoplastic drug at a concentration and volume such that the amount of antineoplastic drug in the container is equal to the calculated dose for one patient but less than the calculated dose for a second patient, the calculated dose is provided to first patient within 5% variance by directly administering the full volume of the solution of antineoplastic drug from the first perfusion container, further the first perfusion container is accompanied by a second top-up perfusion container comprising a solution of antineoplastic drug at a concentration and volume such that the calculated dose is provided within 5% variance by directly administering the full volume of the solution of antineoplastic drug from the first perfusion container and the second top-up container to the second patient.

Perfusion system

The invention relates to an infusion container comprising a sterile, ready-to-use, stable aqueous solution of Midazolam or a pharmaceutically acceptable salt thereof, suitable for direct intravenous infusion to a patient in need thereof. The invention also relates to a novel infusion container having plurality of ports that is suitable for delivering or receiving a sterile fluid, such as the said stable aqueous solution of Midazolam or a pharmaceutically acceptable salt thereof.

Infusion bag of Midazolam for intravenous use

The present invention relates to a method for enabling hospitals or clinics to administer a dose of a drug to patients in need thereof while avoiding steps of manipulation, dilution, reconstitution, dispensing, sterilization, transfer, handling or compounding before intravenous administration. The present invention further relates to a perfusion system comprising different sets of perfusion containers, each container comprising a ready-to-infuse, stable, sterile, aqueous perfusion solution of a drug, wherein the set of perfusion containers alone or in combination provides for direct intravenous administration of a desired dose of the drug to a patient in need thereof, such that the delivered dose is equal to or within &#xb1;5% of the calculated dose.

Perfusion dosage form

Infusion bag of midazolam for intravenous use

The present invention relates to a parenteral dosage form comprising a) a ready-to-infuse, stable aqueous solution comprising diltiazem or its pharmaceutically acceptable salt, pH adjusting agent to provide a pH in the range of 3 to 5 and ethanol, and b) an infusion container filled with said aqueous solution.

Parenteral dosage form of diltiazem

The present invention provides a parenteral dosage form consisting essentially of a solution filled in a container, the solution comprising amiodarone or its pharmaceutically acceptable salt and a sulfo-alkyl ether beta-cyclodextrin in an aqueous vehicle, wherein the solution has a pH in the range of about 2.4 to 3.9 and further wherein the dosage form is sterilized by subjecting the filled container to autoclaving.

Parenteral dosage form of amiodarone

Growing community of inventors

Baroda, India

Samarth Kumar